BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

524632

SHUKRAPHAR

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Shukra Pharmaceuticals Limited Share Price Update

As of the latest trading session, Shukra Pharmaceuticals Limited share price is currently at ₹ 15.99, which is down by ₹ -0.84 from its previous closing. Today, the stock has fluctuated between ₹ 15.99 and ₹ 17.17. Over the past year, Shukra Pharmaceuticals Limited has achieved a return of 71.19 %. In the last month alone, the return has been -25.35 %. Read More...

Shukra Pharmaceuticals Limited fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    700.20

  • P/E Ratio (TTM)

    84.16

  • Beta

    -0.17

  • Book Value / share

    1.23

  • Return on equity

    44.71%

  • EPS (TTM)

    0.19

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    3.16

info icon alternate text

Shukra Pharmaceuticals Limited Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 10.58
Operating Expense 7.49
Net Profit 3.16
Net Profit Margin (%) 29.86
Earnings Per Share (EPS) 0.72
EBITDA 4.94
Effective Tax Rate (%) 22.73
Particulars SEP 2024 (Values in Cr)
Revenue 5.56
Operating Expense 5.70
Net Profit 0.54
Net Profit Margin (%) 9.71
Earnings Per Share (EPS) 0.12
EBITDA 1.68
Effective Tax Rate (%) 39.08
Particulars JUN 2024 (Values in Cr)
Revenue 3.18
Operating Expense 3.10
Net Profit 0.49
Net Profit Margin (%) 15.40
Earnings Per Share (EPS) 0.11
EBITDA 1.53
Effective Tax Rate (%) 38.74
Particulars MAR 2024 (Values in Cr)
Revenue 10.88
Operating Expense 7.04
Net Profit 3.99
Net Profit Margin (%) 36.67
Earnings Per Share (EPS) 3.64
EBITDA 5.81
Effective Tax Rate (%) 23.75
Particulars DEC 2023 (Values in Cr)
Revenue 18.89
Operating Expense 9.93
Net Profit 9.42
Net Profit Margin (%) 49.86
Earnings Per Share (EPS) 8.61
EBITDA 10.11
Effective Tax Rate (%) 1.15
Particulars MAR 2024 (Values in Cr)
Revenue 74.57
Operating Expense 57.51
Net Profit 18.54
Net Profit Margin (%) 24.86
Earnings Per Share (EPS) 16.93
EBITDA 22.22
Effective Tax Rate (%) 6.79
Particulars MAR 2023 (Values in Cr)
Revenue 58.83
Operating Expense 55.59
Net Profit 4.41
Net Profit Margin (%) 7.49
Earnings Per Share (EPS) 11.23
EBITDA 6.56
Effective Tax Rate (%) 0.90
Particulars MAR 2022 (Values in Cr)
Revenue 20.49
Operating Expense 19.55
Net Profit 0.75
Net Profit Margin (%) 3.66
Earnings Per Share (EPS) 4.79
EBITDA 2.96
Effective Tax Rate (%) 26.47
Particulars MAR 2021 (Values in Cr)
Revenue 11.20
Operating Expense 11.26
Net Profit 0.03
Net Profit Margin (%) 0.26
Earnings Per Share (EPS) 0.22
EBITDA 1.60
Effective Tax Rate (%) 60.00
Particulars MAR 2020 (Values in Cr)
Revenue 11.85
Operating Expense 11.78
Net Profit 0.04
Net Profit Margin (%) 0.33
Earnings Per Share (EPS) 0.23
EBITDA 1.65
Effective Tax Rate (%) 82.35
Particulars MAR 2024 (Values in Cr)
Book Value / Share 52.65
ROE % 44.71
ROCE % 44.16
Total Debt to Total Equity 0.10
EBITDA Margin 29.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 64.63
ROE % 21.18
ROCE % 18.84
Total Debt to Total Equity 0.20
EBITDA Margin 11.15
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.43
ROE % 4.69
ROCE % 5.81
Total Debt to Total Equity 0.41
EBITDA Margin 14.49
Particulars MAR 2021 (Values in Cr)
Book Value / Share 99.63
ROE % 0.90
ROCE % 1.35
Total Debt to Total Equity 0.57
EBITDA Margin 16.07
Particulars MAR 2020 (Values in Cr)
Book Value / Share 98.43
ROE % 0.13
ROCE % 0.36
Total Debt to Total Equity 0.46
EBITDA Margin 11.29
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.98
Total Assets 77.83
Total Liabilities 77.83
Total Equity 57.63
Share Outstanding 10959725
Price to Book Ratio 6.20
Return on Assets (%) 23.81
Return on Capital (%) 30.49
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.97
Total Assets 74.96
Total Liabilities 74.96
Total Equity 25.29
Share Outstanding 1565700
Price to Book Ratio 0.73
Return on Assets (%) 5.87
Return on Capital (%) 14.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.28
Total Assets 35.11
Total Liabilities 35.11
Total Equity 16.35
Share Outstanding 1565700
Price to Book Ratio 0.58
Return on Assets (%) 2.13
Return on Capital (%) 3.81
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.50
Total Assets 35.60
Total Liabilities 35.60
Total Equity 15.59
Share Outstanding 1565675
Price to Book Ratio 0.45
Return on Assets (%) 0.52
Return on Capital (%) 0.74
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 33.54
Total Liabilities 33.54
Total Equity 15.41
Share Outstanding 1565675
Price to Book Ratio 0.47
Return on Assets (%) 0.10
Return on Capital (%) 0.15
Particulars MAR 2024 (Values in Cr)
Net Income 19.88
Cash from Operations -4.57
Cash from Investing -1.20
Cash from Financing 12.40
Net change in Cash 6.00
Free Cash Flow -2.81
Particulars MAR 2023 (Values in Cr)
Net Income 4.44
Cash from Operations 3.41
Cash from Investing -4.42
Cash from Financing 4.94
Net change in Cash 3.68
Free Cash Flow 7.91
Particulars MAR 2022 (Values in Cr)
Net Income 1.01
Cash from Operations 8.42
Cash from Investing -1.52
Cash from Financing -6.67
Net change in Cash -0.21
Free Cash Flow 9.97
Particulars MAR 2021 (Values in Cr)
Net Income 0.09
Cash from Operations 0.53
Cash from Investing -1.89
Cash from Financing 1.73
Net change in Cash 0.37
Free Cash Flow 2.32
Particulars MAR 2020 (Values in Cr)
Net Income 0.17
Cash from Operations 1.23
Cash from Investing -3.11
Cash from Financing 1.99
Net change in Cash 0.12
Free Cash Flow 4.46
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2959.45 58.70 29.97 50134.87 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

Shukra Pharmaceuticals Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
15.99 -4.99 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 16.90
  • 26 Days 19.50
  • 10 Days 17.80
  • 50 Days 20.00
  • 12 Days 18.10
  • 100 Days 18.30
  • 20 Days 19.00
  • 200 Days 14.90
16.51 PIVOT

First Support

15.87

First Resistance

17.48

Second Support

14.90

Second Resistance

18.12

Third Support

14.26

Third Resistance

19.09

RSI

27.45

ADX

73.87

MACD

-1.41

Williams % R

-91.15

Commodity Channel Index (CCI)

-158.90

Date

2025-04-30

Week

133862.00

Same Day

85483.00

Month

213903.00

1 Year

-0.18

3 Year

0.16

Over 1 Month

-25.35%

down

Over 1 Year

71.19%

down

Over 3 Months

-31.52%

down

Over 3 Years

247.81%

down

Over 6 Months

133.77%

down

Over 5 Years

140.19%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

Shukra Pharmaceuticals Limited shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
48.92%
Promoter Holdings
50.95%
FII
0.0%
DII
0.11%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Yogesh Biharilal Parikh 8.4E7 (19.18%) Public Shareholding
Renuka Yogesh Parikh 8.4E7 (19.18%) Public Shareholding
Anar Project Private Limited 8.224E7 (18.78%) Shareholding of Promoter and Promoter Group
Parshva Texchem India Private Ltd. 7.51756E7 (17.17%) Shareholding of Promoter and Promoter Group
Navkar Surgical Gujarat 5.16E7 (11.78%) Shareholding of Promoter and Promoter Group
Dakshesh Rameshchandra Shah 4360000.0 (1.0%) Shareholding of Promoter and Promoter Group
Anar Jayeshbhai Patel 4360000.0 (1.0%) Shareholding of Promoter and Promoter Group
Sujay Jyotindra Mehta 3120000.0 (0.71%) Shareholding of Promoter and Promoter Group
Payal Sujay Mehta 2280000.0 (0.52%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Shukra Pharmaceuticals Limited corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
15 Sep 2023 0.5 Final 16 Sep 2023 Equity shares
22 Sep 2022 0.5 Final 22 Sep 2022 Equity shares
19 Sep 2019 0.5 Final 21 Sep 2019 Equity shares
31 Aug 2018 0.5 Final 04 Sep 2018 Equity shares
01 Sep 2017 0.5 Final 05 Sep 2017 Equity shares
Ex-Date Ex-Bonus Ratio
20 Apr 2024 19 Apr 2024 3:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Shukra Pharmaceuticals Limited Share Price

Shukra Pharmaceuticals Limited (Formerly known Relish Pharmaceuticals Limited) was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016. The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing.

The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat.

The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc.

The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals companies around the world.

In FY 2013-14, the Company got approval from Hon'ble High Court of Gujarat for revival of Relish Pharmaceuticals Limited and Amalgamation of Proper Dealcomm Private Limited with the erstwhile Relish Pharmaceuticals Limited and Re-organization of Share Capital of Relish Pharmaceuticals Limited through the Scheme of Arrangement vide Hon'ble High Court of Gujarat order dated 20 December, 2013.

Parent organization Indian Private
NSE symbol [-]
Founded 1993
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Shukra Pharmaceuticals Ltd?

Answer Field

The share price of Shukra Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 15.99.

What is the Market Cap of Shukra Pharmaceuticals Ltd?

Answer Field

The market cap of Shukra Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 7,00.20 Cr. as of now.

What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Shukra Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 27.15 and ₹ 5.75.

How to Buy Shukra Pharmaceuticals Ltd share?

Answer Field

You can trade in Shukra Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Shukra Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 71.19%.

What is the Current Share Price of Shukra Pharmaceuticals Ltd?

Answer Field

Shukra Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 15.99 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Shukra Pharmaceuticals Ltd Share?

Answer Field

The market cap of Shukra Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 7,00.20 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Shukra Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Shukra Pharmaceuticals Ltd share is 84.16.

What is the PB ratio of Shukra Pharmaceuticals Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Shukra Pharmaceuticals Ltd share is 1.23.

How to Buy Shukra Pharmaceuticals Ltd Share?

Answer Field

You can trade in Shukra Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Shukra Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Shukra Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Shukra Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|